Trends in Pharmacotherapy for Bladder Dysfunction Among Children in the United States, 2000 to 2013.
Trends in Pharmacotherapy for Bladder Dysfunction Among Children in the United States, 2000 to 2013.
复制标题
2000 年至 2013 年美国儿童膀胱功能障碍药物治疗趋势。
DOI：
10.1177/0009922816641366
复制
发表时间：
2017
影响因子：
1.6
通讯作者：
Wu,JenniferM
中科院分区：
文献类型：
--
作者：
Kinlaw,AlanC;JonssonFunk,Michele;Steiner,MichaelJ;Conover,MitchellM;Pate,Virginia;Wu,JenniferM
夜间遗尿和失禁等与膀胱相关的问题长期以来一直是普通儿科实践的一部分。临床医生越来越多地针对各种类型的膀胱功能障碍开出药物，但之前没有基于人群的数据。我们使用 MarketScan 32 074 638 名参保儿童的医疗保健索赔数据来估计 2000 年至 2013 年美国按年龄、性别、年份和地理区域划分的使用模式，并评估相关诊断代码。大约每 500 名儿童中就有 1 人服用抗毒蕈碱处方。最常见的处方是奥昔布宁（78%）和托特罗定（17%）。 6 至 10 岁年龄段的发病率最高（65/100 000 人月），女孩比男孩高出 31%，在 2011 年达到顶峰（44/100 000 人月），其中中西部地区最高（59/100 000 人月）。 73% 持有处方的儿童有泌尿生殖系统症状的诊断代码，13% 有先天性异常的诊断代码。需要研究这些药物对儿童的相对有效性和安全性。
Bladder-related issues such as nocturnal enuresis and incontinence have long been a part of general pediatric practice. Increasingly, clinicians are prescribing medications directed at a variety of types of bladder dysfunction, but no prior population-based data exist. We used MarketScan health care claims data on 32 074 638 insured children to estimate utilization patterns by age, sex, year, and geographic region in the United States from 2000 to 2013, and to assess related diagnosis codes. Approximately 1 in 500 children filled an antimuscarinic prescription. The most common prescriptions were for oxybutynin (78%) and tolterodine (17%). Rates were highest at ages 6 to 10 years (65/100 000 person-months), 31% higher for girls versus boys, peaked in 2011 (44/100 000 person-months), and were highest in the Midwest (59/100 000 person-months). Seventy-three percent of children with prescriptions had diagnosis codes for genitourinary symptoms, and 13% had codes for congenital anomalies. Research is needed regarding the comparative effectiveness and safety of these drugs in children.